Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics
10.1124/dmd.111.041558
Saved in:
Main Authors: | Jayaraman, R., Reddy, V.P., Pasha, M.K., Wang, H., Sangthongpitag, K., Yeo, P., Hu, C.Y., Wu, X., Xin, L., Goh, E., New, L.S., Ethirajulu, K. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/106237 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
by: Yong, W.P., et al.
Published: (2014) -
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue
by: Novotny-Diermayr, V., et al.
Published: (2014) -
Histone deacetylases and repression of the gonadotropin genes.
by: Melamed, P.
Published: (2014) -
Role of natural products in modulating histone deacetylases in cancer
by: Merarchi, M., et al.
Published: (2021) -
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
by: Huang, B.H., et al.
Published: (2014)